CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.

Slides:

Advertisements

Similar presentations

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.

Advertisements

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.

La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.

Johan Denollet, PhD the heart failure patient ? Why is a dedicated cardiologist not sufficient for The Netherlands.

Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.

חזק בהגנה לבבית Valsartan in Heart Failure

Heart and Mind Connections: Integrated Strategies for Greater Health Presentation to Senior Leadership.

analysis from the SHIFT study

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Heart Failure Ben Starnes MD FACC Interventional Cardiology

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

Myocardial Ischemia Redefined: Optimal Care in CAD.

Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,

Cognitive Impairment: An Independent Predictor of Excess Mortality SACHS, CARTER, HOLTZ, ET AL. ANN INTERN MED, SEP, 2011;155: ZACHARY LAPAQUETTE.

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Congestive Heart Failure Patient Advocate Joe R. Anderson, PharmD, PhC, BCPS Associate Professor Pharmacy Practice and Internal Medicine University of.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.

Cardiovascular disease in a large cohort of depressed and/or anxious patients Results of the Netherlands Study of Depression and Anxiety N Vogelzangs 1,

New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology

Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.

The Bypassing the Blues Trial Telephone-Delivered Collaborative Care for Treating Post-CABG Depression BL Rollman, B Herbeck Belnap, PR Houck, S Mazumdar,

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.

Cardiovascular disease in persons with anxiety or depressive disorders Nicole Vogelzangs 1,2, Adrie Seldenrijk 1,2, Aartjan TF Beekman 1,2, Hein PJ van.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

CoRPS Center of Research on Psychology in Somatic diseases Depression and anxiety in atrial fibrillation patients - is this undertreated? Susanne S. Pedersen,

CoRPS Center of Research on Psychology in Somatic diseases Quality of life. How to evaluate? Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases Cardiac Psychology: A match made in heaven for patients Susanne S. Pedersen, Professor of Cardiac.

CoRPS Center of Research on Psychology in Somatic diseases The Medtronic Sprint Fidelis lead advisory notification has no adverse impact on patient reported.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

CoRPS Center of Research on Psychology in Somatic diseases Positive and negative emotions and heart disease Susanne S. Pedersen, Professor of Cardiac Psychology.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

CoRPS Center of Research on Psychology in Somatic diseases Psychosocial support Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases Patients with an ICD Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases Type D personality as a risk factor for adverse vascular outcomes in diabetes patients: A role.

Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.

CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.

CoRPS Center of Research on Psychology in Somatic diseases The patient perspective on LVAD implantation – a neglected dimension? Prof. dr. Susanne S. Pedersen,

Type D Personality and Chronic Kidney Disease as Predictors of Pro- and Anti- Inflammatory Cytokine Levels in Heart Failure Interleukin-6 (IL-6), tumor.

CoRPS Center of Research on Psychology in Somatic diseases Inflammation, Mediation and Type D personality Multiple inflammatory biomarkers as mediators.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

The effects of mindfulness meditation training on Type D personality Center of Research on Psychology in Somatic diseases Dr. Nina Kupper Dr. Sietze Graafsma.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.

CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.

CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.

CoRPS Center of Research on Psychology in Somatic diseases ICD patients with anxiety: what to do? Susanne S. Pedersen, Professor of Cardiac Psychology.

Vital exhaustion predicts the progression of myocardial infarction-

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

Updates From NOTION: The First All-Comer TAVR Trial

The long-term impact of psychotherapy in patients with refractory angina Patel PA2, Ali N1, Thapar S1, Sainsbury PA1 1Department of Cardiology, Bradford.

Revascularization in Patients With Left Ventricular Dysfunction:

Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

with type 2 diabetes without heart failure?

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

Creatinine clearance (mL/min) n All-cause mortality (%)

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.

Presentation transcript:

CoRPS Disclosures None

CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S. Pedersen, Professor of Cardiac Psychology

CoRPS Affiliations Prof.dr. Susanne S. Pedersen CoRPS - Center of Research on Psychology in Somatic diseases, Tilburg University, The Netherlands Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands Department of Cardiology, Odense University Hospital & Institute of Psychology, Southern University of Denmark, Denmark

CoRPS

Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Depression and mortality Rumsfeld et al. Am Heart J 2005;150:961-7 N = 634 Depression prevalence: 22.6% HR: 1.75 [95% CI: ]* HR: 1.41 [95% CI: ]* * Adjusted analysis

CoRPS Depression and mortality Rollman et al. J Cardiac Fail 2012;18: N = 471 All-cause: HR: 3.1 [95% CI: ]* Cardiac: HR: 2.7 [95% CI: ]* * Adjusted analysis

CoRPS Cardiovascular death-free survival stratified by depression symptoms and rhythm- versus rate-control Frasure-Smith et al. Circulation 2009;120: N=947 comorbid AF-HF Atrial Fibrillation and Congestive Heart Failure trial Rate-control (i.e., beta- blockers and digoxin) versus rhythm-control (i.e., antiarrhythmic medications and electrical cardioversion) 32% had BDI-II scores 14 (mild to moderate symptoms of depression) No differential impact of rate vs. rhythm control within depressed vs. non depressed

CoRPS Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Anxiety, depression, social isolation and mortality Friedmann et al. Am Heart J 2006;152:940.e1-940.e8 Cumulative hazard functions: Adjusted HR: 2.25; 95% CI: Adjusted HR: 0.55; 95% CI: Adjusted HR: 1.03; 95% CI: N = 153

CoRPS Anxiety moderates the effect of rhythm versus rate control on mortality Frasure-Smith et al. Circ Heart Fail 2012; N=947 comorbid AF-HF Adjusted HR: 0.55; 95% CI: ASI = tendency to fear and catastrophize in response to bodily symptoms No main effect of ASI Benefit of rhythm vs. rate control in high ASI patients Adjusted HR: 1.24; 95% CI: Benefit

CoRPS Anxiety and heart failure outcomes: Event- free survival De Jong et al. Heart & Lung 2011;40: N = 147 Highest anxiety group more likely to (i) visit the ED, (ii) be hospitalized, (iii) die - HR: 2.2 [95% CI: 1.1 – 4.3]; p =.03

CoRPS Anxiety and heart failure outcomes: Non adherence with medication De Jong et al. Heart & Lung 2011;40: N = 147

CoRPS Non adherence: A mediator of the anxiety / event-free survival relationship De Jong et al. Heart & Lung 2011;40: N = 147

CoRPS Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Impact of Type D on cardiac mortality* N = 232 Schiffer et al. Int J Cardiol 2010;142:230-5 * Adjusted for age, sex and LVEF

CoRPS Impact of Type D on all-cause mortality N = 641 (Mean FU = 3 yrs) Pelle, Pedersen, Denollet et al. Circ Heart Fail 2010:3:261-7

CoRPS Predictors of 12-month disease-specific and generic health status (adjusted) Disease-specific health (MLWHFQ) Mental health (SF-36; MCS) Generic physical health (SF-36; PCS) OR (95%CI) p p p Type-D personality2.5 ( ) ( )<.001ns Depressive symptoms3.2 ( ).01ns 3.2 ( ).009 NYHA functional classns 2.4 ( ).04 Diuretics3.3 ( )..04ns Spironolactonens Long-acting nitratesns Psychopharmacans Baseline health status3.4 ( ) ( )< ( ).002 Agens Sexns LVEF1.1 ( ).02ns N = 166 Schiffer, Pedersen et al. Eur J Heart Fail 2008;10:802-10

CoRPS Schiffer, Denollet et al. Heart 2007;93:814-8 Self-management Heart failure patients with Type D: report more cardiac symptoms (OR: 6.4; 95% CI: ; p <.001) worry more about their symptoms (OR: 2.9; 95% CI: ; p <.01) but are less likely to consult doctor/nurse (OR: 2.7; 95% CI: ; p =.02)

CoRPS Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Confounding with disease severity Stability of measures – timing of assessment Actionability based on current evidence Challenges

CoRPS Confounding of psychological factors with disease severity

CoRPS Type D and primary care HF patients Type D personality was not related to measures of disease severity: o NYHA class ( 2 = 3.90; p =.14) o Goldman’s Specific Activity Scale (SAS) ( 2 = 4.50; p =.11) N = 363 Scherer, Herrmann-Lingen et al. Herz 2006;31:347-54

CoRPS De Jonge et al. J Psychosom Res 2007;63: LVEF post-MI in depression and Type D Post-MI depression Type D personality Equality test - (%)+ (%)OR (95% CI) - (%)+ (%)OR (95% CI)Zp LVEF <45% ( ) ( )3.29<.001 Charlson > ( ) ( ) Previous MI ( ) ( ) PTCA ( ) ( ) CABG ( ) ( ) N = 1205 MI patients

CoRPS Stability of psychological factors

CoRPS Measure X Time Effect F(1,119)=52.0, p<.0001 Entry score End score Measure X Time Effect F(1,119)=42.1, p<.0001 (c) HEALTH COMPLAINTS (b) MOOD: Negative Affect (a) TYPE D PERSONALITY Entry score End score Denollet. Psychosom Med 2005;67:89-97 Entry: baseline assessment N = 121 End: following rehabilitation Stability of mood states and Type D over time

CoRPS Incorporation of psychological factors in clinical practice Interventions

CoRPS Increase level of evidence – large- scale studies and registries

CoRPS Overview Risky psychological profiles: o Depression o Anxiety o Type D personality Challenges and future directions Take home message

CoRPS Cardiology & psychology: Perhaps not a such strange marriage...

CoRPS Take home message The psychological profile of the patient matters Psychological factors are not standardly assessed in clinical cardiology practice nor can a proxy be derived from the medical records Screen and monitor – we need to know who they are Informed decision with respect to which measures to use (e.g. issue of confounding, stability etc.) Optimalization of HF care (e.g. adjunctive intervention)